Management of Primary Hyperaldosteronism
For unilateral primary aldosteronism, laparoscopic adrenalectomy is the definitive treatment of choice, while bilateral disease requires lifelong medical therapy with mineralocorticoid receptor antagonists (MRAs), with spironolactone as first-line agent. 1
Treatment Algorithm Based on Disease Lateralization
Unilateral Disease (Aldosterone-Producing Adenoma)
Laparoscopic adrenalectomy is the gold standard for unilateral PA, offering potential cure of hypertension in approximately 40% of patients and significant blood pressure reduction in most others 2, 3. The most recent 2025 Endocrine Society guideline and 2024 consensus documents strongly support this approach 3, 1.
Preoperative Preparation
- Treat patients for 8-10 weeks before surgery with MRAs to correct metabolic abnormalities (hypokalemia) and control blood pressure 4
- This preoperative optimization reduces surgical risk and improves outcomes
Surgical Considerations
- Laparoscopic approach is superior to open surgery, with shorter hospital stays and fewer complications 2
- Requires an experienced surgeon in laparoscopic adrenalectomy 2
- Partial adrenalectomy is not recommended as it results in persistent hypertension in up to 10% of cases 2
Post-Surgical Management
- Critical caveat: Recommend generous sodium diet immediately post-surgery to avoid hyperkalemia from contralateral adrenal suppression 2
- Monitor for persistent hypoaldosteronism requiring fludrocortisone (occurs in up to 5% of patients) 2
- Blood pressure typically normalizes within 1-6 months but can continue improving up to 1 year 2
- Many patients remain hypertensive post-surgery due to coexistent essential hypertension, particularly with older age and longer hypertension duration 2
Bilateral Disease (Idiopathic Adrenal Hyperplasia)
Medical therapy with MRAs is the treatment of choice for bilateral PA, as surgery yields only 19% cure rates and is not recommended 2, 1.
Pharmacologic Management
First-Line: Spironolactone
Spironolactone is the preferred MRA due to superior potency, lower cost, and greater availability 1, 3. The 2025 Endocrine Society guideline explicitly recommends spironolactone over other MRAs when cost and availability are considered 3.
Dosing Strategy
- Start low: 12.5-25 mg daily as a single dose 2
- Titrate gradually to find the lowest effective dose, up to maximum 100 mg/day (some sources cite up to 400 mg/day for resistant cases) 2, 4
- Usual effective dose: 100-200 mg daily 4
Monitoring
- The 2025 guideline recommends monitoring renin levels during MRA therapy 3
- If hypertension remains uncontrolled and renin is suppressed, titrate MRA upward 3
- This represents a shift toward renin-guided dosing rather than arbitrary dose escalation
Side Effects (Dose-Dependent)
- Gynecomastia: 6.9% at <50 mg/day, 52% at >150 mg/day 2
- Erectile dysfunction in men
- Menstrual irregularities in women (exact incidence unknown) 2
- Muscle cramps
Second-Line: Eplerenone
Eplerenone is the alternative when spironolactone side effects are intolerable, particularly anti-androgenic effects 2, 1, 3. The 2024 consensus documents emphasize its role in avoiding gynecomastia and sexual dysfunction 1.
Key Differences from Spironolactone
- 50% less potent than spironolactone, requiring 2-3 times higher doses 2, 1
- Must be dosed twice daily due to shorter half-life 2
- Starting dose: 25 mg twice daily 2
- More selective for mineralocorticoid receptors, avoiding progesterone and androgen receptor effects 2
- Higher cost is the main limitation 2
Alternative Agents
When MRAs are insufficient or contraindicated:
- Amiloride 10-20 mg/day (epithelial sodium channel blocker) 4
- Add thiazide diuretics, beta-blockers, or calcium channel blockers for additional blood pressure control 4
- Small doses of triamterene can be added to avoid high-dose spironolactone side effects 2
Renal Function Considerations
Critical warning: Administer spironolactone and eplerenone with extreme caution in stage III chronic kidney disease (GFR <60 mL/min/1.73 m²) due to hyperkalemia risk 2. Avoid MRAs entirely in stage IV disease 2.
Important paradox: Treating PA (surgically or medically) frequently unmasks underlying renal dysfunction, as PA causes reversible glomerular hyperfiltration that disguises declining GFR and albuminuria 2. Approximately 30% of PA patients reveal CKD after treatment 5.
Special Populations
Glucocorticoid-Remediable Aldosteronism (Familial Hyperaldosteronism Type 1)
Treat with glucocorticoids (dexamethasone or prednisone) taken at bedtime to suppress early morning ACTH surge 2. This is the only form of PA where glucocorticoids are first-line therapy. Use the lowest dose that normalizes blood pressure and potassium to avoid iatrogenic Cushing's syndrome 2. Add MRAs if glucocorticoid alone fails to normalize blood pressure 2.
Pregnancy and Advanced Age
Medical treatment is especially indicated as first-line therapy in these populations 6.
Treatment Goals and Outcomes
The Primary Aldosteronism Outcome (PASO) criteria should guide treatment objectives, focusing on both biochemical and clinical response 1. Treatment aims to:
- Normalize blood pressure
- Eliminate excessive aldosterone production
- Reverse target organ damage (left ventricular hypertrophy, atrial fibrillation risk)
- Reduce cardiovascular and renal morbidity/mortality
Evidence of superiority: A 2025 meta-analysis demonstrated that adrenalectomy provides superior long-term regression of left ventricular mass (3.5% greater reduction) and 32% reduction in left ventricular hypertrophy risk compared to 19% with MRAs 7. Shorter hypertension duration predicts greater benefit from surgery 7.
Common Pitfalls to Avoid
- Don't skip preoperative MRA therapy before adrenalectomy—this 8-10 week period is essential for metabolic correction
- Don't forget post-surgical sodium supplementation—hyperkalemia from contralateral suppression is a real risk
- Don't use MRAs in stage IV CKD—hyperkalemia can be life-threatening
- Don't assume surgery cures all patients—only ~40% achieve complete hypertension cure; most still need some antihypertensive therapy
- Don't overlook renin monitoring—the 2025 guideline emphasizes renin-guided MRA titration for optimal outcomes